BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Movement Disorder Society Release: Caffeine Demonstrates Potential Benefits for Treatment of Parkinson's Disease


6/18/2012 12:16:49 PM

DUBLIN – A study evaluating the use of caffeine to treat motor effects in Parkinson’s disease was presented today at the 16th International Congress of Parkinson’s Disease and Movement Disorders.

Previous studies have consistently demonstrated caffeine to lower risk of Parkinson’s disease, though the effects of caffeine in Parkinson’s patients have yet to be adequately evaluated.

Dr. Ron B. Postuma and colleagues at Montreal General Hospital conducted a six-week randomized controlled trial of caffeine in 61 Parkinson’s patients to assess the effects upon excessive daytime somnolence, motor severity and other non-motor symptoms. While only providing borderline improvement in excessive somnolence, the study did show caffeine to improve objective motor measures, which suggests that a long term investigation of caffeine is warranted.

Prof. K. Ray Chaudhuri, of Kings College Hospital, London, states “This randomized placebo controlled study of caffeine is a significant step forward in establishing evidence base for treatment of non-motor symptoms and excessive daytime somnolence in Parkinson’s. The study is well performed and although, the primary outcome measure of Epworth (Sleepiness Scale) is not significantly altered, there is an emerging signal of improving somnolence on clinical global impression with additional improvements in motor state. In clinical practice this translates to experience of beneficial effect of caffeine in patients with excessive daytime somnolence. This highly needed study should pave the way for a large scale multicenter international study addressing effect of caffeine in the treatment of EDS and related complaints in Parkinson’s disease.”

About the 16th International Congress of Parkinson's Disease and Movement Disorders

Meeting attendees are gathered to learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson's disease. More than 4,500 physicians and medical professionals from 80 countries will be able to view over 1,600 scientific abstracts submitted by clinicians from around the world.

About The Movement Disorder Society

The Movement Disorder Society, an international society of over 3,500 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about The Movement Disorder Society, visit www.movementdisorders.org.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES